Top

Published in:

01-04-2019 | Electrocardiography | IM - PHYSICAL EXAMINATION

Hypocalcemia and hypophosphatemia after treatment with zoledronic acid in a patient with AL amyloidosis

Authors: Antonella Tufano, Domenico Rendina, Paolo Conca, Beniamino Matani, Giovanni Di Minno

Published in: Internal and Emergency Medicine | Issue 3/2019

Excerpt

Zoledronic acid (Zol) is the most powerful third generation aminobisphosphonate, can be intravenously (IV) administered, and is commonly used in patients with metabolic and neoplastic bone disorders, including multiple myeloma (MM). Zol reduces osteoclastic activity and promotes cellular apoptosis and can induce both hypocalcemia (HypoCa) and hypophosphatemia (HypoP), usually mild and asymptomatic. The risk of symptomatic severe HypoCa and HypoP, requiring specific treatment, is low, and has been described in patients with additional predisposing risk factors, such as low 25OHD₃, chronic kidney disease (CKD), and/or liver damage [1‐3]. …

Kreutle V, Blum C, Meier C, Past M, Müller B, Schütz P, Borm K (2014) Bisphosphonate induced hypocalcaemia—report of six cases and review of the literature. Swiss Med Wkly 144:w13979PubMed

Clark SL, Nystrom EM (2016) A case of severe, prolonged, refractory hypophosphatemia after zoledronic acid administration. J Pharm Pract 29(2):172–176CrossRefPubMed

Kaur U, Chakrabarti SS, Gambhir IS (2016) Zoledronate induced hypocalcemia and hypophosphatemia in osteoporosis: a cause of concern. Curr Drug Saf 11(3):267–269CrossRefPubMed

Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schönland S, Hegenbart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G (2012) New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 30(36):4541–4549CrossRefPubMed

Wu X, Feng J, Cao X, Zhang L, Zhou D, Li J (2016) A typical immunoglobulin light chain amyloidosis: spontaneous vertebral compression fracture, liver involvement, and bone marrow involvement report of 3 cases and review of the literature. Medicine (Baltimore) 95(36):e4603CrossRef

Title: Hypocalcemia and hypophosphatemia after treatment with zoledronic acid in a patient with AL amyloidosis
Authors: Antonella Tufano
Domenico Rendina
Paolo Conca
Beniamino Matani
Giovanni Di Minno
Publication date: 01-04-2019
Publisher: Springer International Publishing
Keywords: Electrocardiography
Electrocardiography
Chronic Kidney Disease
Hypocalcemia
AL Amyloidosis
Zoledronic Acid
Published in: Internal and Emergency Medicine / Issue 3/2019
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-019-02048-w

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Hypocalcemia and hypophosphatemia after treatment with zoledronic acid in a patient with AL amyloidosis

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2019

Is there a role for lumbar puncture in early detection of subarachnoid hemorrhage after negative head CT?

Pitfalls in the triage and evaluation of patients with suspected acute ethanol intoxication in an emergency department

Chronic diarrhea: an unusual clinical presentation of vitamin B12 deficiency?

Short- vs long-course antibiotic therapy for pneumonia: a comparison of systematic reviews and guidelines for the SIMI Choosing Wisely Campaign

An unusual calf lesion in an immunocompromised patient

Safety and efficacy of sucrosomial iron in inflammatory bowel disease patients with iron deficiency anemia

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page